Introduction
Vulvodynia has been defined as a 'vulvar pain of at least 3 months' duration, without clear identifiable cause, which may have potential associated factors'. 1 The description is based on the site of pain, whether it is localised (e.g. vestibulodynia, clitorodynia), generalised or mixed, and whether it is provoked (e.g. insertional, contact), spontaneous or mixed; onset (primary or secondary) and temporal pattern (intermittent, persistent, constant, immediate, delayed). 1 Vulvodynia has been recognised as the most common type of chronic pelvic pain, with a growing incidence and prevalence of 12% in the community, and is the most frequent cause of dyspareunia in premenopausal women, with a strong effect on sexual functioning and women's quality of life. [2] [3] [4] [5] [6] It occurs in women of all ages and ethnic groups. 7, 8 It is not the result of by inflammation or infection, either neurological disorders or neoplasia, although various causes have been submitted, including immune, hormonal and genetic factors, as well as altered urinary oxalates, embryological abnormalities and neuropathic changes. 6, 9 Vulvodynia is therefore a complex disease that is difficult to treat. It is recommended that treatment should be holistic, focusing not only on the primary site of the pain but also on its consequent interference with sexual functioning and women's quality of life. 9 Although there are several interventional therapies (medical, surgical, behavioural, cognitive-behavioural and alternative treatments), there is no consensus concerning their efficacy. 6, [10] [11] [12] [13] According to some studies, the lack of consensus can be explained by the absence of knowledge about the aetiology of vulvodynia and the methods of treatment remain clinically based on the few randomised controlled trials relating to this disease. [14] [15] [16] [17] Although there has been an increased number of studies about the treatment of vulvodynia, few have discussed drug treatment itself for vulvar pain and, to our knowledge, no systematic review has been undertaken to investigate the most effective type of medication. This review has chosen to approach drug treatment by following a rigorous methodology in an attempt to reduce the risk of bias, as medications are widely used as the initial approach to vulvodynia in clinical practice.
The objective of this study is to conduct a systematic review of randomised placebo controlled studies which assess medications used to treat vulvar pain in vulvodynia.
Methods
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement. [18] [19] [20] The protocol for this systematic review was registered on PROSPERO 21 and can be accessed at http://www.crd.york.ac.uk/PROSPERO/ display_record.php?ID=CRD42016049009.
The research question was developed using the population, intervention, comparator and outcome framework. A literature search, with no language restriction, was performed using MEDLINE (accessed by PubMed), Web of Science, Cochrane Library, EBSCO Academic and LILACS databases to identify relevant studies published from 1985 to September 2016. This study included randomised clinical trials (RCT) that compared any kind of medication (topical, oral and injectable medications) for vulvodynia treatment with placebo or with another medication in adult patients (i.e. patients ≥18 years) with the diagnosis of vulvodynia without a specific description. We considered trials that studied outpatients and evaluated at least the impact in vulvar pain.
Exclusion criteria were as follows: (1) studies that assessed other modalities of treatment but only topical, oral and injectable medications; (2) studies comparing drug treatments with other modalities such as physical therapy, cognitive behavioural therapy and acupuncture, among others; (3) duplicate publications or sub-studies of included trials. In this case, the publication with the longer follow-up was chosen.
Titles and abstracts of retrieved articles were independently evaluated by two investigators (G.M.V.P. and M.V.C.M.). Abstracts that did not provide enough information for analysis of the intervention or the methodology regarding the inclusion and exclusion criteria defined in this review were retrieved for full-text evaluation. Subsequently, the two investigators independently evaluated fulltext articles and determined study eligibility. Any disagreements among researchers related to the eligibility criteria of the previously selected studies were discussed in a meeting and the decision was made by consensus. A third researcher (Z.S.N.R.) helped in this process.
Data extraction and quality assessment
The two investigators independently conducted data extraction, and the third investigator resolved disagreements. Study quality assessment was performed by two reviewers independently using the Cochrane Handbook for Systematic Reviews of Intervention 22 version 5.1.0. The studies were judged as 'low risk', 'high risk' or 'unclear risk' for the following categories: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, selective reporting and other biases (for biases that do not fit into these categories). 22 
Data analysis
During the review period, interventions and analysis of the outcomes of the selected studies were different, thus it was not possible to perform a meta-analysis. The analysis was therefore restricted to a systematic review. We performed a calculation to obtain the percentages of pain reduction from the VAS mean scores presented in the articles. We used the mathematical expression:
Percentage of pain reduction ¼ pain at the end of treatment or follow-up -pain on baseline pain on baseline Â 100
Results
A flow diagram of search and selection is shown in Figure 1 . The database search resulted in 826 articles (342 PubMed, 8 LILACS, 38 Cochrane Trials, 334 Web of Science, 104 EBSCO). In all, 475 were excluded after duplicates were found in the databases, resulting in 351 articles. The screening of the titles and abstracts selected 83 studies. Of these, 69 were excluded because they did not meet the selection criteria. We evaluated the full text of 14 randomised clinical trials for eligibility and nine studies were excluded because they associated drugs with other modalities of treatment. Therefore, five randomised clinical trials were included in qualitative synthesis ( Figure 1 ). The main characteristics of the five included trials are presented in Table 1 . The number of participants varied from 30 to 133 among the eligible studies, resulting in a total of 297 patients assessed. Regarding the interventions, one study assessed a drug with systemic effect and administered orally, desipramine 25 mg (topical lidocaine 5% was also tested). Two studies tested injectable drugs, botulinum toxin A (intramuscular) and enoxaparin 40 mg (subcutaneous). Two studies evaluated topical medications: nifedipine (2% and 4%) and cream with cutaneous fibroblast lysate. All those five trials were placebo-controlled. Table 2 shows the extraction of data on pain reduction, which was assessed by Q-tipped Cotton Test and scored by the visual analogue scale (VAS) with mean values for pain reduction results. Mean pain reduction results. *This trial presented the mean pain reduction index value using a 100-point scale. **Placebo (oral) and placebo (topical); lidocaine (topical) and placebo (oral); desipramine (oral) and placebo (topical); desipramine (oral) and lidocaine (topical). The authors made three measurements using VAS.
***Active cream: oil-in-water emulsion-based cream with water, octyldodecanol, decyl oleate, glyceryl stearate, propylene glycol, glycerin, stearic acid, wheat germ oil, cetyl alcohol, borage seed oil, dimethicone, cetyl palmitate, carbomer and formulated with 0.05% of cutaneous lysate. ****Placebo: the identical oil-in-water-based cream in which the cutaneous lysate was replaced by water.
Petersen et al. 23 found in the Botox group and in the placebo group, mean pain scores of 7.48 and 7.63, respectively, before the intervention, and 5.14 and 5.13 after the intervention. Pain reduction was seen in 31.3% in the Botox group and 32.8% in the placebo group.
Bornstein et al., 15 using a 100-point scale, reported a mean score of 91.5 before the intervention and 53.4 after the intervention in the placebo group. In the intervention group, the 2% nifedipine group had a mean score of 86 before the intervention and 56.2 after the intervention. In the 4% nifedipine group, the mean score was 87 before the intervention and 63.5 after the intervention. Pain reduction rates at the end of treatment were 41.6% for the placebo group, 34.7 for the 2% nifedipine group and 27% for the 4% nifedipine groups. At the end of the follow-up, pain reduction rates were as follows: 42.4% (placebo), 45 .3% (2% nifedipine) and 15.5% (4% nifedipine).
Foster et al. 17 performed three measurements using VAS and added the three measurements to the result. In the placebo and oral placebo group, the mean score before the intervention was 21.48 and 12.83 after the intervention. In the oral placebo and topical lidocaine group, the mean scores were 19.3 and 12.61 before and after the intervention, respectively. In the topical placebo and oral desipramine group, the mean score before the intervention was 19.59 and 11.52 after the intervention. Finally, in the oral desipramine and topical lidocaine group, the mean scores before and after the intervention were 19.97 and 8.6, respectively. Pain reduction rates at the end of treatment were 40.3% (placebo-placebo), 34.7% (placebo-lidocaine), 41 .2% (placebo-desipramine) and 56.9% (lidocaine-desipramine). At the end of the follow-up, the groups had the following pain reduction indices: 24.7% (placebo), 33.8% (placebo-desipramine) and 19% (lidocaine-desipramine). The pain reduction index in the placebo-placebo group was not reported at the end of the follow-up. Donders et al. 24 presented two intervention phases separated by a washout period of 1 week in a cross-over study. The mean scores of the groups before the intervention were 7.57 in the group that started with active cream and 7.23 in the group that started with placebo; after the intervention, the mean scores were 6.0 and 6.69, respectively. Pain reduction rates in the groups were as follows: 20.7% (active cream) and 7.5% (placebo) at the end of the treatment, and 32.9% (active cream) and 13.8% (placebo) at the end of the follow-up.
Farajun et al.
14 assessed vestibular sensitivity with a swab test and found a mean score before the intervention of 8.2 in the enoxaparin group and 7.5 in the placebo group. After the intervention, the mean scores were 6.25 in the enoxaparin group and 6.6 in the placebo group. Pain reduction rates after treatment and post-follow-up were 23.8% and 29.3% (enoxaparin) and 12.0% and 9.3% (placebo), respectively.
The assessment of the risk of bias, based on the Cochrane Handbook for Systematic Reviews of Intervention, 22 is presented in Figure 2 . The random sequence generation was unclear in three studies and low-risk in two studies. Allocation concealment was unclear in four studies and only one study presented a low risk. Blinding of participants and personnel was judged low-risk in four studies and high-risk in one study. Blinding of outcome assessment was low-risk in four studies and unclear in one study. Selective reporting was low-risk in three studies and highrisk in two studies. Other biases were low-risk in four studies and high-risk in one. The high risk is due to carryover effects.
Discussion

Main findings
This systematic review evaluating the medications used in the treatment of vulvar pain in vulvodynia showed no significant advantage of any medication over placebo, which was even more effective than drugs in some cases. This finding adds to evidence of a strong psychological component in vulvodynia. Five studies analysed 297 patients with localised provoked vulvodynia with 6 weeks to 6 months of treatment and 12 weeks to 10 months of follow-up. The studies used the cotton swab test and VAS.
The cotton swab test has many variations in terms of location in the vestibules tested as well as the order and amount of force used during palpation. 25 The studies analysed showed variations of the vulvar regions during the performance of this test. 14, 15, 17, 23, 25 Standardisation of the tested areas could avoid problems of pain classification in patients. 26, 27 VAS is a useful instrument being considered as a measure of treatment efficacy. 28, 29 All studies used this scale, varying in only the score, from 0 to 10 or a scale of 100 points, and one study carried out three measures.
In an attempt to organise the information obtained in the articles evaluated, we used an equation to achieve the percentage of pain reduction. However, this percentage variation in the pain index score seems to be insufficient as an indicator of the effectiveness of the treatments. For example, taking only pain reduction indexes based on the proposed equation, the combined therapy used by Foster et al. 17 had the highest reduction rate (56.9%). However, in their conclusion the researchers attested to the failure of medications to reduce pain when compared with placebo.
Strengths and limitations
The main strength of this study is to have made an objective comparison between the main drugs used in the treatment of vulvodynia, without association with other treatment modalities that could represent a confounding factor in the evaluation of the response to pain reduction. Our review followed the methodology recommended by the Cochrane Handbook, with a comprehensive search in different databases, independent evaluation of titles and abstracts by two reviewers, as well as data extraction and quality assessment. Considering that the evaluation of the outcome of interest is subjective, it is essential to follow a strict methodology, including the evaluation of the individual quality of the studies. Non-randomised studies, which were included in other reviews, carry a greater risk of bias.
The limitations of this study were the small number of studies included in this review, despite the inclusion of controlled and randomised studies, and the lack of metaanalysis. 10, 30 Due to the paucity of randomised placebocontrolled trials for the medical treatment of vulvodynia, we had to include underpowered studies, even though these studies might report greater effects of interventions compared with larger studies. 31 This may have impacted the outcome.
Interpretation
The choice of drugs and doses in the studies was empirical or based on previous studies. Foster et al. 17 have selected two medicinal products for the treatment of vulvodynia which include an oral tricyclic antidepressant (desipramine) with central action and a topical anaesthetic (lidocaine) 32 with peripheral action.
33, 34 The authors tested not only oral and topical monotherapy but also combined therapy of both drugs, hypothesising that the combination therapy would have a superior effect to monotherapy. 17 After observing a significant increase in vestibular mast cells, subepithelial heparanase activity, and intraepithelial neuroproliferation in previous experiments with women with vulvodynia, 35, 36 Farajun et al. 14 suggested that heparanase appears to be involved in vestibular stroma degradation with penetration of nerve fibres through the basal epithelial membrane, causing vestibular hypersensitivity. As enoxaparin was shown to be a potent inhibitor of heparanase activity, 37, 38 the researchers evaluated the efficacy of enoxaparin in the treatment of vulvodynia but organised both the treatment and the dosing periods empirically.
Based on studies comparing chronic anal fissure and muscle hypertonicity with inflammatory infiltrate found in this fissure and vulvodynia, Bornstein et al. 15 investigated the efficacy of the topical use of nifedipine, a calcium channel blocker, 39 in the treatment of vulvodynia. Petersen et al. 23 chose to study botulinum toxin after evidence concerning its use in the treatment of vestibulodynia had been published. They also studied relief of dyspareunia and improvement of sexual function and quality of life in patients with vestibulodynia. [40] [41] [42] [43] Finally, Donders et al. 24 presented an active cream comprising the crude lysate of fibroblasts cultured in women with localised provoked vulvodynia. This lysate exhibits anti-inflammatory and healing properties as well as scar management and skin rejuvenation. [44] [45] [46] [47] In addition, the authors speculated that the lysate may improve the resistance to mucosal friction during sexual activity. 24, 47 The placebo effect is described as a psychobiological phenomenon occurring in the brain after the patient is subjected to an inert substance or to simulated treatment with verbal cues of clinical benefit. 48 There was no single placebo effect, but several effects were seen. 49, 50 Expectations of future events may modulate anxiety and induce physiological changes through reward mechanisms. The mesolimbic dopaminergic system is the main rewards network; it can be activated when a patient awaits clinical improvement after the use of placebo. This process was observed for pain in the study by Scott et al. 51 Monotherapy or the combination of desipramine and lidocaine have not been more successful than placebo in reducing vulvar pain. The authors 17 suggest that improvement with placebo treatment may not indicate a true placebo effect but rather a therapeutic benefit of cream massage or the natural history of vulvodynia, 52 as well as the attention paid by the nurse contact or beneficial effects of the moisturel composition (petrolatum and dimethicone).
The difference between active cream and placebo products was not statistically significant in the study of Donders et al. 24 because of a carryover effect and the small sample number. The authors did not comment on whether there was a placebo effect in the non-difference between the products throughout the study.
In the study by Bornstein et al., 15 it is possible that the support patients received from their teammates and the team involved in the study may have aided in pain relief. The application of the ointment and not the action of nifedipine may contribute to the reduction of pain intensity in the study groups. Thus, the researchers reported that oral nifedipine is not expected to reduce pain more than a placebo.
Petersen et al. 23 speculated that both botulinum toxin and placebo induced a placebo effect because 50% of participants in each of the two groups experienced a two-point decrease in VAS, indicating a response not induced by Botox itself but by other factors. Pain relief may be related to distention of the pelvic muscles after injection. In addition, the attention received from the physician and the prospect of a new cure, when previous treatments failed, may have influenced patient outcome. 23 Farajun et al. 14 reported no placebo effect.
Conclusion
This systematic review showed no significant advantage of any medication over placebo in the treatment of vulvar pain in vulvodynia. There is not sufficient evidence to support which drug is better indicated to treat vulvar pain. There is a need for further studies evaluating topical monotherapies for the treatment of vulvodynia, as they are the main drugs used in clinical practice.
